Short Amphipathic Peptides Can Deliver Gene-Silencing siRNA into Human Liver Cancer Cells
A newly designed 12-amino-acid cell-penetrating peptide effectively delivered siRNA into human liver cancer cells at low concentrations, silencing target genes through RNA interference.
Quick Facts
What This Study Found
The researchers designed 12-mer amphipathic helical peptides incorporating α,α-disubstituted amino acids (dAAs) to stabilize their secondary structure. Peptides with hydrophobic dAAs that adopted a helical conformation showed strong cell-penetrating ability.
One peptide containing dipropylglycine (a specific dAA) formed stable complexes with siRNA at appropriate size and surface charge for intracellular delivery. This peptide achieved effective RNA interference — meaning it successfully silenced target genes — in human hepatoma (liver cancer) cells at remarkably short peptide length and low concentrations of both the peptide and siRNA.
Key Numbers
How They Did This
In vitro laboratory study using human hepatoma (liver cancer) cell lines. Researchers designed a series of 12-amino-acid amphipathic helical peptides with different α,α-disubstituted amino acids and characterized their secondary structures in solution. They measured cell-penetrating ability, then tested the peptides' capacity to form complexes with siRNA and deliver it into cancer cells, measuring RNA interference efficiency as the outcome.
Why This Research Matters
siRNA therapies have enormous potential to treat diseases by silencing harmful genes, but getting siRNA into cells remains the central delivery challenge. Most current solutions use lipid nanoparticles, which have limitations. Cell-penetrating peptides offer an alternative delivery platform that could be more precise and versatile. This study's contribution — achieving effective delivery with a very short, well-defined peptide at low concentrations — brings the field closer to practical, peptide-based gene therapy delivery systems.
The Bigger Picture
Cell-penetrating peptides are part of a broader effort to solve the 'delivery problem' in gene therapy. While lipid nanoparticles currently dominate siRNA delivery (as seen in FDA-approved drugs like patisiran), peptide-based delivery could offer advantages in targeting, customization, and manufacturing. This work on short, structurally stabilized peptides contributes to the foundation for next-generation delivery vehicles that could make gene-silencing therapies more accessible and effective, particularly for liver diseases including hepatocellular carcinoma.
What This Study Doesn't Tell Us
This is an in vitro study using cancer cell lines only — no animal or human testing was performed. Cell-penetrating ability in a dish doesn't guarantee effectiveness in a living organism, where the peptide would face enzymatic degradation, immune responses, and biodistribution challenges. Specific quantitative data on silencing efficiency and concentrations were not provided in the abstract. Long-term toxicity was not assessed.
Questions This Raises
- ?How does this peptide-based siRNA delivery system perform in animal models compared to lipid nanoparticle approaches?
- ?Can these short amphipathic peptides be modified to target specific cell types beyond liver cancer cells?
- ?What is the stability and half-life of these peptide-siRNA complexes in blood and tissue environments?
Trust & Context
- Key Stat:
- 12 amino acids, effective delivery The peptide achieved RNA interference in liver cancer cells at remarkably short length and low concentration, suggesting efficient design
- Evidence Grade:
- This is a preclinical in vitro study testing peptide-siRNA delivery in human cancer cell lines. While it demonstrates proof-of-concept, it is at the earliest stage of therapeutic development with no animal or human data.
- Study Age:
- Published in 2020, this study is relatively recent and contributes to an active area of research in peptide-based drug delivery that continues to evolve rapidly.
- Original Title:
- siRNA delivery using amphipathic cell-penetrating peptides into human hepatoma cells.
- Published In:
- Bioorganic & medicinal chemistry, 28(8), 115402 (2020)
- Authors:
- Furukawa, Kaori, Tanaka, Masakazu(2), Oba, Makoto(3)
- Database ID:
- RPEP-04808
Evidence Hierarchy
Frequently Asked Questions
What are cell-penetrating peptides and why do they matter?
Cell-penetrating peptides (CPPs) are short chains of amino acids that can cross cell membranes, which most molecules can't do on their own. They matter because many promising drugs — especially gene-silencing molecules like siRNA — can't get inside cells where they need to work. CPPs act as delivery vehicles, carrying these therapeutic cargoes through the cell membrane and into the cell interior.
Could this technology be used to treat liver cancer in people?
Not yet — this is early laboratory research. The peptide successfully delivered siRNA into liver cancer cells in a dish, which is a necessary first step. Before it could become a treatment, it would need to be tested in animal models, optimized for stability in the body, and then go through clinical trials in humans. That process typically takes many years.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04808APA
Furukawa, Kaori; Tanaka, Masakazu; Oba, Makoto. (2020). siRNA delivery using amphipathic cell-penetrating peptides into human hepatoma cells.. Bioorganic & medicinal chemistry, 28(8), 115402. https://doi.org/10.1016/j.bmc.2020.115402
MLA
Furukawa, Kaori, et al. "siRNA delivery using amphipathic cell-penetrating peptides into human hepatoma cells.." Bioorganic & medicinal chemistry, 2020. https://doi.org/10.1016/j.bmc.2020.115402
RethinkPeptides
RethinkPeptides Research Database. "siRNA delivery using amphipathic cell-penetrating peptides i..." RPEP-04808. Retrieved from https://rethinkpeptides.com/research/furukawa-2020-sirna-delivery-using-amphipathic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.